Sample size requirements for evaluating heart valves with constant risk events

Area of Science:

• Biomedical Engineering
• Clinical Trials Methodology
• Medical Device Regulation

Background:

• The U.S. Food and Drug Administration (FDA) has revised guidance for clinical studies of new heart valves.
• Current FDA requirements necessitate comparing complication rates of study valves against established Objective Performance Criteria (OPCs).
• OPCs are derived from historical data of approved devices and can vary by complication type and valve material (mechanical or tissue).

Purpose of the Study:

• To describe a method for calculating sample size requirements for heart valve clinical studies.
• To provide a formula for determining required "valve-years" based on Objective Performance Criteria (OPCs).
• To establish the minimum follow-up duration needed to meet FDA guidelines.

Main Methods:

• The study employs a one-sample hypothesis test framework as specified by the FDA.
• A method utilizing the Poisson distribution is developed to compute sample size.
• The formula calculates the necessary "valve-years" of follow-up for a given OPC.

Main Results:

• A straightforward formula is derived for calculating required "valve-years" for any specified OPC.
• At the FDA-recommended OPC level of 1.2% per year, the minimum required follow-up is approximately 800 valve-years.
• This method simplifies sample size computation for heart valve studies.

Conclusions:

• The described method offers a practical approach to meet FDA sample size and follow-up duration requirements for heart valve clinical trials.
• Adherence to the calculated valve-years ensures adequate statistical power for evaluating new heart valve safety and efficacy.
• The Poisson distribution-based formula provides a key tool for researchers and regulatory bodies in planning and assessing heart valve studies.